Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification
Axel Ursenbach, Yvon Ruch, Baptiste Hoellinger, Anne Fuchs, Stéphanie Caspar, Frédérick Jegou, David Rey, Samira Fafi‐Kremer, Thibault Mésplède, Pierre Gantner
Abstract
Dolutegravir/lamivudine (DTG/3TC) has a high genetic barrier against the development of human immunodeficiency virus drug resistance. We report 2 cases of R263K + M184V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.
Topics & Concepts
DolutegravirLamivudineResistance mutationVirologyMedicineViral loadVirusAntiretroviral therapyBiologyReverse transcriptaseGeneticsPolymerase chain reactionGeneHepatitis B virusHIV/AIDS drug development and treatmentHepatitis B Virus StudiesHIV Research and Treatment